HALO Halozyme Loading...

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
Time Author Thesis Company / ticker Signal Since call Position Source
06:26
Aug 21
Гоша Анатолий Радченко | Финансовы…
Анатолий Радченко | Финансовый кружок
Halozyme undervalued with buybacks and royalties.
Halozyme has revenue growing around 23%, profit margins near 25%, shrinking share count, royalty income, and a falling forward P/E despite price appreciation; DCF fair value is near 160 versus 106.
HALO Halozyme Long 1ST — —
12:23
Aug 16
frenchv33921
Holding HALO long despite 50% gain
Author discloses an active, high-conviction long position in HALO, choosing to hold despite a +50% gain in three months, signaling continued upside belief rather than taking profits.
HALO Halozyme Long — —
03:20
Aug 10
Lee Hyuk-jin 3PRO TV
3PRO TV
Royalty-based biotech companies offer high earnings visibility.
CMO/CDMO and SC formulation biotech companies like Halozyme and Alteogen offer high earnings visibility due to royalty-based models, making them attractive in a high-rate environment.
HALO Halozyme Long 1ST — —
Log in to see ideas

About HALO Investor Commentary

Across the available history and selected sources, Buzzberg tracks HALO (Halozyme) across 9 sources: 11 bullish vs 0 bearish calls from 10 authors. Historical directional balance: 48% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 23 total trade ideas tracked. Latest voices: Гоша, frenchv33921, Lee Hyuk-jin.